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ABSTRACT  32 
Background: Physical activity (PA) is important in the management of Cystic Fibrosis (CF) and 33 
is associated with a number of beneficial effects. PA assessment is not commonplace or 34 
consistent clinical practice, therefore understanding of PA in adults with CF remains limited. 35 
The purpose of this review was to evaluate PA levels in this population and compare PA to 36 
global recommendations and non-CF peers. 37 
Methods: The Preferred Reporting Items for Systematic Reviews and Meta-analyses 38 
guidelines were utilised to inform the review process. Original research was identified and 39 
screened against inclusion/exclusion criteria. Quality was assessed, data extracted and a 40 
narrative synthesis undertaken to describe the findings.  41 
Results: Adults with CF did not achieve recommended PA guidelines and step count targets 42 
in 5/8 studies where assessment was possible. No significant differences in PA were found 43 
between CF and non-CF peers in 3/5 studies. Associations between PA and improved lung 44 
function were inconsistent with 4/9 studies finding a positive association. Evidence for an 45 
association between PA and higher exercise capacity was stronger with all 4 studies reviewed 46 
reporting a positive association. Quality ratings were low across all studies. 47 
Conclusions: PA in adults with CF is largely comparable to their non-CF peers, despite being 48 
insufficiently active to achieve PA recommendations. Assessment tools used and outcomes 49 
reported are variable, many of which do not provide sufficient information to assess relevant 50 
components of PA. There is a requirement for high quality studies designed specifically to 51 
explore PA in adults with CF, ideally employing standardised PA assessment methods. 52 
 53 
KEYWORDS 54 
PRISMA; respiratory disease; exercise; quality of life. 55 
 56 
ABBREVIATIONS 57 
PA, Physical activity; SB, Sedentary behaviour; PRISMA, Preferred Reporting Items 58 
for Systematic Reviews and Meta-analyses; MVPA, Moderate-Vigorous Physical 59 
Activity; METs, Metabolic Equivalents. 60 
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1. INTRODUCTION 61 
Life expectancy of patients with Cystic Fibrosis (CF) continues to increase with improvements 62 
in treatments over recent decades, resulting in a greater proportion of adults living with CF [1]. 63 
Physical activity (PA) is associated with a number of potential benefits in the management of 64 
CF including positive effects on lung function [2], mucociliary clearance [3], bone health [4] 65 
and hospitalisation frequency [5]. Higher levels of PA are also associated with improved 66 
exercise capacity [6], which is in turn associated with reduced mortality in patients with CF [7]. 67 
PA promotion is therefore recommended as part of the routine management of CF [8,9]. 68 
Despite this PA assessment is not common or consistent [8]. However, CF presents patients 69 
with a number of potential barriers to PA including; physical symptoms (breathlessness, 70 
increased cough, fatigue), high treatment burden and low self-efficacy for PA [10]. 71 
PA can be defined as any bodily movement produced by contraction of skeletal muscle that 72 
substantially increases energy expenditure, this includes leisure-time PA, occupational PA 73 
and exercise [11]. Various self-reported and objective methods are reported in the literature 74 
for the assessment of PA in adults with CF, however inconsistencies in measurement tools, 75 
outcome measures reported and study design used limit our understanding of PA behaviour 76 
and its health associations in this population. It is generally accepted that patients with CF 77 
engage in less PA than their non-CF peers, this is particularly evident for vigorous PA [12], 78 
however this finding is inconsistent across the multiple assessment methods reported in the 79 
literature. Furthermore, little is known about sedentary behaviour (SB) in this population 80 
despite high levels of SB being negatively associated with health outcomes and 81 
cardiometabolic diseases in the general population, even among individuals achieving PA 82 
guidelines of 150 minutes of moderate-to-vigorous PA a week [13]. High levels of SB are 83 
considered as an independent risk factor for cardiovascular disease and mortality [13], yet 84 
remain relatively unexplored in an ageing CF population. 85 
There are currently no PA guidelines specifically developed for individuals with CF, although 86 
guidelines for the general population appear to be applicable with some modifications 87 
depending on disease progression [14]. For the purpose of this review, the global physical 88 
activity guidelines outlined by the World Health Organisation (WHO) were used when 89 
interpreting reported PA levels. It is recommended that adults (18-64 years) should take part 90 
in at least 150 minutes of moderate-vigorous intensity aerobic PA (MVPA) or 75 minutes of 91 
vigorous intensity PA throughout the week [15]. The variation in outcome measures reported 92 
in the studies reviewed makes it difficult to compare reported levels of PA to recommended 93 
guidelines, comparison is therefore only possible in a small number of the studies reviewed. 94 
Achieving 10,000 steps daily also provides a reasonable estimate of daily activity and 95 
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individuals achieving this typically meet the recommendations of 150 minutes MVPA per week 96 
[16]. Therefore assessing step count can help to quantify PA and through the use of the indices  97 
can provide information for screening, surveillance and intervention evaluation [16]. 98 
A large proportion of the PA research conducted in CF populations has been undertaken with 99 
children and adolescents [8] and may not be transferable to adult populations. It is well 100 
documented that PA declines with age in the general population [17] which may also be 101 
exacerbated by worsening disease severity in CF. Given the increasing life expectancy and 102 
number of adults living with CF, an understanding of PA levels in adult populations is required. 103 
It is important that healthcare professionals are familiar with PA guidelines, engage patients 104 
in conversation around PA and are able provide advice and signpost patients to relevant 105 
resources.  106 
1.1 Aims 107 
The purpose of this review therefore, is to: 1) Establish the physical activity levels of adults 108 
with CF. 2) Compare reported PA levels between CF patients and their non-CF peers. 3) 109 
Examine the associations between PA and markers of health in adults with CF. 110 
 111 
2. METHODS 112 
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 113 
guidelines were utilised to inform the review process [18]. Studies that assessed PA in adults 114 
with CF and were published from database inception to Feb 28th 2018 were identified. An a 115 
priori defined protocol was utilised to identify relevant articles that were then systematically 116 
screened against inclusion and exclusion criteria. The published protocol can be accessed via 117 
the PROSPERO database (CRD42018088434). 118 
A narrative synthesis was performed to provide a summary of the assessment tools used, 119 
outcomes reported and overall quality of PA assessment [19]. An assessment of the quality of 120 
evidence was made to support the strength of the findings and conclusions made. It was not 121 
possible to conduct a meta-analysis due to the wide variation in the methods used to assess 122 
PA, the inconsistency of outcome measures reported and the low quality ratings of the 123 
available literature.  124 
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2.1 Search strategy and initial screening  125 
Electronic databases SCOPUS (Elsevier, EMBASE & ScienceDirect), Web of Science, 126 
Medical Literature Analysis and Retrieval System Online (MEDLINE) (Cumulative Index of 127 
Nursing and Allied Health Literature (CINAHL), SportDiscus & Psychinfo) and Oalster grey 128 
literature were searched using search terms individually tailored for each database (Figure 1). 129 
Databases were selected to provide comprehensive coverage of indexed journals, which 130 
publish studies from relevant healthcare and PA fields. Title and abstract screening was 131 
employed to identify relevant articles and remove articles that were not eligible, this was 132 
preferred to applying search limits or ‘NOT’ terms. Reasons for removing articles at this stage 133 
included; non-CF population, paediatric population, no original data reported, not peer 134 
reviewed and written in languages other than English. No restrictions were applied to the date 135 
of publication, owing to the limited number of studies in a relatively novel field. The search 136 
terms yielded 1166 hits, representing 671 unique articles (Figure 2). A further 565 articles 137 
were removed during title and abstract screening, using the same criteria as above, resulting 138 
in screening of 106 full-text articles. Full-text articles were screened against inclusion and 139 
exclusion criteria, leaving 18 articles for data extraction (Figure 2). Study characteristics are 140 
presented as supplementary material (additional file 1) References of all included papers were 141 
screened, although this did not yield any additional articles. 142 
Figure 1 – Boolean search terms 143 
OR AND 
‘physical activity’ ‘Cystic Fibrosis’. 
‘habitual activity’,  
‘sedentary behaviour’  
‘accelerometers’  
‘motion sensors’  
‘actigraph’  
‘geneactiv’  
‘sensewear’  
‘activpal’  
‘HAES’  
‘caltrac’  
‘IPAQ’  
& variations on each term  
V8 – 04/03/2019   Page 6 of 27 
 
Figure 2 - PRISMA flowchart 144 
 145 
2.2 Application of eligibility criteria 146 
Inclusion criteria included; measurement of physical activity and/or sedentary behaviour (SB) 147 
using a measurement tool validated for use in the general adult population and/or adults with 148 
CF. Baseline PA and/or SB reported prior to any interventions. Preferable but not essential 149 
criteria included; data reported for clinical outcome measures (lung function, exercise 150 
capacity, quality of life (QoL)). 151 
 152 
Exclusion criteria included; paediatric (<18 years), non-CF or mixed populations where adult 153 
and paediatric data were not separated, use of non-validated methods for assessing PA and/or 154 
SB, no reporting of PA and/or SB or no baseline data available. Additionally, studies not written 155 
in English, providing no original data or that were not peer reviewed were also excluded. 156 
Studies that were written as abstracts only rather than full papers were also excluded. No 157 
restrictions were applied for study design. Randomised control trials, interventional and 158 
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observational studies were considered based on satisfaction of the inclusion/exclusion criteria 159 
outlined above. Five articles were excluded as ‘paediatric population’ although they reported 160 
data for mixed adult and paediatric populations or defined adults by criteria other than ≥18 161 
years [6,20–23]. Whilst these articles may contain potentially relevant data the original authors 162 
were not able to provide the data on the request of the reviewers in the given time frame. 163 
Additionally, all studies that were excluded and used accelerometry are listed alongside the 164 
reason for exclusion (additional file 2).  165 
2.3 Data extraction 166 
A modified version of the ‘Cochrane Data Extraction Form’, from the Cochrane Handbook for 167 
Systematic Reviews of Interventions (version 5.1) [24] was used. The form was modified to 168 
include relevant participant characteristics and outcome measures. Two authors (JS, ED) 169 
independently extracted the data, discrepancies were resolved through discussion, with a third 170 
reviewer (LB) where necessary. Extracted information included: Article characteristics; year of 171 
publication, journal, funding source, publication type. Study setting; study population and 172 
participant demographics and baseline characteristics. Study methodology; recruitment and 173 
study completion rates; outcomes and times of measurement. Information for assessment of 174 
the risk of bias.  175 
2.4 Risk of bias assessment 176 
Two reviewers (JS, ED) independently assessed the risk of bias for the included studies using 177 
the Cochrane risk of bias tool, agreement was reached between the reviewers although a third 178 
reviewer (LB) was available if required (Table 1).  179 
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Table 1 – Risk of bias assessment of studies included for review.  180 
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Bhudhikanok 1998 [42] high high high high low low 
Cox 2016 [5] high high high high low low 
Currie 2017 [37] high high high high low low 
Decorte 2017 [33] low high high high low low 
Elkin 2001 [39] high high high unclear low low 
Enright 2004 [38] low low unclear high low low 
Enright 2007 [43] high low high high low low 
Gruet 2016 [35] unclear high high high low low 
Haworth 1999 [34] high high high high low low 
Hollander 2005 [32] high high high high low low 
Ionescu 2003 [40] high high high high low unclear 
Rasekaba 2013 [36] high high high high low low 
Savi 2013 [31] high high high high low low 
Savi 2015 [30] high high high high low high 
Savi 2015 [28] high high high high high high 
Street 2006 [41] high high high high low low 
Troosters 2009 [12] high high high high low low 
Ziai 2016 [29] high high high high low low 
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2.5 Data synthesis 181 
A narrative synthesis was used to describe the data in three sections; 1) PA levels of adults 182 
with CF in comparison to global PA recommendations, 2) PA levels of adults with CF in 183 
comparison to non-CF peers, 3) The relationship between PA and clinical outcome measures.  184 
2.5.1 Moderate-Vigorous Physical Activity 185 
Studies reporting a measure of PA described with a time unit, were compared to the 150 186 
minutes of MVPA per week recommendation. In studies only measuring PA over 5 days the 187 
150 minutes of MVPA recommendation was interpreted as 30 minutes per day on 5 days of 188 
the week. 189 
2.5.2 Metabolic Equivalents (MET) 190 
MET refers to metabolic equivalent, where 1 MET is the rate of energy expenditure while sitting 191 
at rest and is equivalent to an oxygen uptake of 3.5 millilitres per kilogram (kg) per minute, or 192 
a caloric consumption of 1kcal/kg/hour. METs are used to attempt to classify PA intensity in a 193 
number of studies reviewed, for example, a 3 MET activity expends 3 times the amount of 194 
energy used at rest. For the purposes of this review the following definitions are applied; 195 
moderate intensity (3-6 METs), vigorous activity (>6 METs) [25]. METs can also be expressed 196 
as MET-minutes, whereby the metabolic equivalence of an activity is multiplied by the number 197 
of minutes spent engaging in the activity. For example engaging in an activity of 3 METs for 198 
30 minutes is equal to 90 MET-minutes. Consequently, 150 minutes MVPA per week equate 199 
to 450 MET-minutes per week, therefore recommendations for MET minutes per week are 200 
≥450 MET-minutes per week.  201 
2.5.3 Steps  202 
Whilst it is not possible to make comparisons with the WHO guidelines, the following indices 203 
were applied to classify PA based on the number of daily steps reported; Sedentary (<5000), 204 
low active (5000-7499), somewhat active (7500-9999), active (≥10,000), highly active 205 
(>12,500) [16]. Total physical activity described as time spent in weight bearing activity or 206 
walking was reported in two studies. It is not possible to compare levels of PA among adults 207 
with CF to recommended guidelines for MVPA using this data as there is no description of 208 
intensity.  209 
2.5.4 Energy expenditure 210 
Energy expenditure (EE) represents the sum of resting energy expenditure and the thermic 211 
effect of digestion in addition to physical activity [25]. Studies in the current review reported 212 
total energy expenditure (TTE) and not specifically the energy expenditure associated with 213 
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PA. Whilst it has been proposed that adherence to recommended PA guidelines yields an 214 
energy expenditure of ~1000 kcal·wk-1, which is associated with improved health outcomes 215 
[26], TEE alone does not provide suitable information to assess if adults with CF achieved 216 
recommended guidelines for PA.  217 
2.5.5 PA indices  218 
The Baecke and Physical Activity Self-Administered Questionnaire (AQAP) questionnaires 219 
provide a PA index. The work domain classified occupations as; Low activity (1), Moderate 220 
activity (3), High activity (5). Sport and leisure domains were calculated by assigning a MET 221 
value for specified activities and assessing the time spent engaging in such activities again 222 
resulting in a PA score between 1-5. The sum of the three categories (work, sport, leisure) 223 
provides a total PA score between 3-15 [27]. These data do not provide information on minutes 224 
of PA therefore cannot be compared to PA guidelines.  225 
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3. RESULTS 226 
3.1 Reporting of PA in adults with CF 227 
In the 18 studies reviewed 33 separate outcome measures were reported using 11 228 
assessment tools including 1 accelerometer (SenseWear Pro 3 armband) and 10 separate 229 
self-report questionnaires (Table 2). 230 
Table 2 – Summary of assessment tools utilised and outcome measures reported. 231 
Accelerometer  
SenseWear Pro 3 armband 
[5,12,28–31] 
 
 
Total energy expenditure (Kcal/day) 
Steps per day 
Total METs 
Total PA (mins/day) 
Light PA (mins/day) 
Moderate PA (mins/day) 
Vigorous PA (mins/day) 
Moderate to vigorous PA (mins/day) 
Questionnaire  
Habitual Activity Estimation Scale 
(HAES) [31] 
Total inactivity (min/day) 
Total activity (min/day) 
Baecke 
[32–34] 
Activity score 
Activity factor for sedentary lifestyle (1.5, 1.7, 2.1) 
Work index 
Sport index 
Leisure index 
Physical Activity self-Administered 
Questionnaire (AQAP) 
[35] 
Sport index 
Leisure index 
Global index 
International Physical Activity 
Questionnaire (IPAQ) 
[36] 
Work (min/week) 
Transport (min/week) 
Domestic (min/week) 
Leisure (min/week) 
Walking (min/week) 
Moderate (min/week) 
Vigorous (min/week) 
Recall questionnaires 
[37–43] 
METs (weekly) 
METs (daily) 
METs (1.5 Light) (hrs/week) 
METs (4 Moderate) (hrs/week) 
METS (6 Hard) (hrs/week) 
METs (10 Very hard) (hrs/week) 
Lying time (min/day) 
Energy expenditure (Kcal/day) 
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3.2 Levels of PA in adults with CF compared to recommended PA guidelines 232 
Comparison between PA levels in adults with CF and global physical activity guidelines was 233 
only possible in 8 [5,12,28-30,,36, 37,43] of the 18 studies reviewed. Adults with CF only met 234 
PA guidelines in 3 [5,36,37] of the 8 studies, only one of which used objective methods to 235 
assess PA [5]. Table 3 displays the findings for the 13 studies which did not include a control 236 
group.  237 
3.2.1 Studies reporting objectively assessed PA 238 
Accelerometry was used in 3 of these studies [5,28,29]  although only two reported MVPA 239 
[5,28] with a third reporting step count and TEE [29]. Of the two studies reporting MVPA, 240 
participants achieved recommended PA guidelines in one [5]. In the study in which participants 241 
did not achieve recommended PA guidelines, step count was also reported, which would 242 
indicate that patients were ‘somewhat active’, despite not meeting guidelines for MVPA [28]. 243 
Despite using similar assessment methods in groups of comparable disease severity and 244 
participant characteristics the two studies reported different levels of MVPA. The final study 245 
[29] using objective assessment only reported step count, however these values appear to be 246 
similar to those previously reported [28], with both studies reporting ‘somewhat active’ cohorts 247 
achieving 8874 and 9508 steps respectively. 248 
3.2.2 Studies reporting self-reported PA  249 
One study [37] used a 7-day recall questionnaire to assess PA, and whilst this tool has 250 
previously been validated for use in CF [20], reported levels of PA are high in contrast to 251 
objectively assessed PA, with patients exceeding PA recommendations, reporting a mean of 252 
282 minutes of moderate, hard or very hard PA per week. Three studies used the Baecke 253 
questionnaire [32–34], with a fourth using the AQAP [35], all of which report PA as an activity 254 
score and therefore results cannot be compared to PA guidelines. Furthermore one study did 255 
not provide group means, which prevented interpretation [32]. Gruet et al. (2016) reported an 256 
overall PA score of 9 (of a possible 15) which may suggest that the population studied were 257 
moderately active [35]. Haworth et al. (1999) reported an activity score of 7.6 which likely 258 
represents low levels of activity in the study group [34]. Decorte et al. (2017) reported 2.6, 2.3 259 
and 3.2 for work, sport and leisure time indices respectively, which suggests that occupational 260 
activity and engagement in sport were low in the population studied, whilst leisure time activity 261 
was higher [33].  262 
Two studies reported mean daily METs [38,40] assessed using recall questionnaires, which 263 
does not provide information for comparison to recommended PA guidelines. Both studies 264 
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reported similar levels of PA (36.7 and 37.6 daily METs, respectively) which were reported to 265 
be comparable to non-CF young adults [38].  266 
Energy expenditure was reported based on self-reported PA in one study [39]. Whilst it is not 267 
possible to make assumptions about PA levels from energy expenditure, the data reported  268 
indicates that TEE in the cohort studied (2071.39 Kcal) is comparable to what could be 269 
predicted for a typical sedentary/low active adult [25].  270 
The final studies reported total PA (time spent walking or doing sport) and weight bearing PA 271 
using self-report techniques [41,42]. The data reported did not include any information about 272 
intensity, which again prevents interpretation in the context of WHO recommended guidelines. 273 
The two studies reported considerably different values with Street et al. (2006) describing what 274 
could be considered as an active cohort (engaging in 11.3hrs per week of PA, including 275 
walking and sport) whilst data provided by Bhudikanok et al. (1998) would suggest that the 276 
cohort were inactive (engaging in 3hrs per week of weight bearing PA). It is possible that the 277 
two report different aspects of PA which is not clear from the methods described. 278 
3.2.3 Sedentary behaviour (SB) 279 
No studies assessed SB, although lying time was reported in one study, finding no significant 280 
difference between adults with CF (452.1 mins/day) and their non-CF peers (493.5 mins/day)  281 
(P=0.11) [31]. Inactivity, assessed using the HAES, was also reported and was not different 282 
between groups (367 vs. 376.6 mins/day for CF and non-CF respectively (P=0.74)) [31], 283 
however inactivity describes insufficient levels of PA to meet guidelines and not necessarily 284 
SB [45]. 285 
 286 
Table 3 – Comparison between reported PA in adults with CF and PA recommendations. 287 
 288 
 289 
[Insert Table 3 here – attached as additional file] 290 
 291 
 292 
3.3 Levels of PA in adults with CF compared to their non-CF peers 293 
Whilst recommended PA guidelines provide a reference value to assess PA in adults with CF, 294 
it is also well recognised that a large proportion of the general adult population do not meet 295 
recommended PA guidelines [17]. It may therefore be more appropriate to compare adults 296 
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with CF to comparable non-CF control groups rather than public health guidelines to determine 297 
if differences exist between the cohorts. Five studies [12,30,31,36,43] reported PA levels for 298 
a comparable non-CF control group, PA was therefore compared between these groups 299 
(Table 4). 300 
3.3.1 Studies reporting objectively assessed PA 301 
Three studies reported objectively assessed PA [12,30,31]. Time spent engaging in MVPA 302 
was significantly higher in the control group when compared to adults with CF in one study 303 
[12]. No significant differences were found between groups across any other outcome reported 304 
in the remaining studies, additionally, the significant difference found by Troosters et al. (2009) 305 
was found in activity above moderate intensity, with no difference at light intensity or in daily 306 
step count [12]. Step count was reported in two studies, neither found a significant difference 307 
between groups, however in both studies the control group would be considered as ‘active’ 308 
based on the daily number of steps (10281 and 10591 steps respectively), whereas each of 309 
the CF groups failed to meet this threshold (9398 and 9161 steps respectively) [12,30]. 310 
Although there is evidence to suggest that there are beneficial effects associated with taking 311 
10,000 steps, cut-points such as this should be interpreted with caution.  312 
3.3.2 Studies reporting self-reported PA  313 
Three studies used self-report tools to assess PA [31,36,43]. PA was higher in the non-CF 314 
control group in 1 study [36], there were no significant differences in the remaining 2 studies 315 
[31,43]. The significant difference observed between the CF and non-CF groups was found 316 
for total PA (MET min.week) (5309 and 7808 respectively, (P=0.011)) [36]. No significant 317 
differences were found between groups for MVPA, additionally, Rasekaba et al. (2013) 318 
described comparable levels of PA across domestic, leisure, moderate-vigorous domains, with 319 
reduced total activity being explained by reduced PA in work and transport domains [36]. The 320 
proportion of adults with CF and non-CF controls who met recommended guidelines for PA 321 
was also comparable with 93% in each group [36].  322 
One study used both a validated questionnaire (HAES) and an accelerometer [31]. No 323 
significant correlation was observed between PA assessed using the objective or subjective 324 
methods (P>0.05), with self-reported PA being over-estimated in both groups, which may 325 
suggest an influence of measurement tool on PA [31].  326 
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Table 4 – Comparison between reported levels of PA in adults with CF and 327 
comparable non-CF control groups. 328 
 329 
 330 
[Insert Table 4 here – attached as additional file] 331 
 332 
 333 
3.4 Relationship between PA and clinical outcome measures 334 
Thirteen studies explored the relationship between PA and other clinical outcome measures 335 
(lung function, body mass index (BMI), exercise capacity, exacerbation frequency) 336 
[5,12,40,42,43,28–31,34,36,37,39]. Whilst the remaining 5 studies  [32,33,35,38,41] reported 337 
data on some of these outcome measures no correlations with PA were performed or reported. 338 
3.4.1 Lung Function 339 
Five studies reported on the relationship between lung function expressed as FEV1 or FEV1% 340 
predicted and objectively assessed PA [5,12,28,30,31]. Though MVPA was not different 341 
across categories of disease severity (FEV1 <40, 40-60, 60-80 >80% predicted), participants 342 
engaging in 30 minutes or more MVPA per day had higher lung function than those engaging 343 
in less than 30 minutes MVPA [5]. Time spent engaging in MVPA was also positively 344 
associated with FEV1% predicted (P=0.04) [28]. Troosters et al. (2009) did not find a 345 
correlation between MVPA and FEV1, although number of steps was positively correlated with 346 
near significance with FEV1 (R=0.39, P=0.08) [12]. Savi et al. (2015) also found no correlation 347 
between MVPA and lung function [30]. MVPA was not reported by Savi et al. (2013), who 348 
reported on energy expenditure, finding a significant correlation between FEV1 and activity 349 
energy expenditure during both week days (r=0.436, P=0.05) and weekends (r=0.435, 350 
P=0.05) [31].  351 
Four studies reported the relationship between lung function and self-reported PA 352 
[36,37,40,43]. No significant difference in FEV1% was found between participants who 353 
achieved recommended PA guidelines compared to those who did not achieve guidelines [37]. 354 
No relationship was found between FEV1 and self-reported PA, although low PA was 355 
associated with reduced vital capacity (VC) and total lung capacity (TLC) (P<0.01) [43]. Higher 356 
PA (MET.min.week) was associated with better lung function (FEV1), although the relationship 357 
was weak (R=0.26, P<0.05) and not statistically significant when analysing males alone, which 358 
may indicate gender differences in PA levels [36]. Patients with severe impairment (FEV1 359 
<45% predicted) were less active than those with mild impairment (FEV1 >65% predicted) 360 
(P<0.01), with no difference between moderate and severe impairment [40]. 361 
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3.4.2 Exercise capacity  362 
Four studies explored the relationship between exercise capacity and PA, all of which 363 
assessed PA using objective methods [5,12,30,31]. All found positive associations between 364 
PA (Total PA ((R=0.51, P=0.02)) [31] and MVPA ((ẞ=0.59, P=0.002, (R2=0.32)), (R=0.44 365 
p=0.01)) [5,12,30]) and exercise capacity (VO2peak [5,12,30] and 6-minute walk test distance 366 
[31]). This relationship was not evident when using the HAES questionnaire to assess PA [31]. 367 
3.4.3 Exacerbations  368 
Two studies explored the relationship between exacerbation and hospitalisation frequency 369 
and objectively assessed PA [5,28]. More frequent exacerbations were associated with lower 370 
PA, although this was not significant once corrected for other clinical covariates [28]. Time 371 
spent engaging in MVPA was moderately, yet significantly correlated with reduced need for 372 
hospitalisation (rs=-0.3, P=0.05) [5]. 373 
3.4.4 Body composition 374 
Three studies explored the relationship between body composition and self-reported PA 375 
[36,40,43]. Lower PA was associated with lower fat free mass (FFM) [40,43] but not BMI [36]. 376 
Four studies [34,39,40,42] explored the relationship between self-reported PA and bone 377 
mineral density (BMD), all of which reported a positive association between higher PA and 378 
higher BMD ((r=0.249, P,0.05), (r=0.3, P<0.01),(r=0.53, P<0.01)) [34,39,40] with the exception 379 
of Bhudikanok et al. (1998) who reported no association [42]. 380 
3.4.5 Blood glucose control 381 
Two studies reported on the association between blood glucose control and PA, using 382 
objective [29] and self-reported PA assessment  [37]. No significant association between blood 383 
glucose control and PA was reported in either study [29,37] .  384 
3.4.6 Quality of Life (QoL) 385 
Only one study reported on quality of life, finding higher scores for QoL in patients achieving 386 
recommendations for MVPA when compared to those who did not (P<0.05) [5]. 387 
4. DISCUSSION 388 
In the majority of studies reviewed adults with CF fail to meet recommended PA and step 389 
count guidelines. Non-CF peers also failed to meet guidelines, with comparable levels of PA 390 
between adults with CF and their non-CF peers. There was low quality evidence to support 391 
associations between lung function, exercise capacity and PA. Associations between PA and 392 
V8 – 04/03/2019   Page 17 of 27 
 
clinical variables were more evident in studies using objective PA assessments, when 393 
compared to those using self-reported PA.  394 
4.1 Achievement of recommended PA guidelines 395 
Adults with CF did not achieve recommended PA guidelines and daily step count targets in 396 
five out of the eight studies in which comparison to guidelines was possible. However, their 397 
non-CF peers also failed to achieve recommended guidelines in two out of five studies. Many 398 
of the assessment tools used did not provide sufficient information about frequency, intensity 399 
and time of PA to allow for comparison to guidelines. Whilst it is recommended that patients 400 
meet PA guidelines it is also worth noting that a small increase in PA levels is associated with 401 
beneficial effects on health outcomes and risk of all-cause mortality, even when recommended 402 
levels are not achieved. Such health benefits can be achieved by individuals moving from the 403 
category of ‘no activity’ to ‘some levels of’ of activity [15].    404 
4.2 Physical activity in adults with CF compared to non-CF peers 405 
No significant differences in PA were found between groups in 3 of the 5 studies with 406 
comparable control groups. The differences observed between groups were reported in work 407 
and transport domains, suggesting variation in lifestyle and employment opportunities in adults 408 
with CF when compared to their non-CF peers in one of these studies [36]. Individuals with 409 
CF are more likely to work in jobs which are sedentary or involve light work, with two thirds of 410 
patients with CF reporting CF as an obstacle to their career, with over half reporting being 411 
limited in their work by CF [46]. Occupational PA in patients with CF may warrant further 412 
investigation. In the second study, the differences between groups were observed at moderate 413 
intensities and above [12]. Classifying PA intensity remains problematic in clinical populations. 414 
Activity intensity is classified using cut-points which are derived using device specific energy 415 
expenditure prediction equations [47], which may not be appropriate for CF populations as no 416 
CF specific cut-points exist. Raw data analysis is recommended as best practice in PA 417 
research [48] and cut-points derived from raw data are available [49], which increases 418 
research control of the data. Unfortunately, these methods were not employed in any of the 419 
studies reviewed and have not been examined in patients with CF to date. Future research 420 
should look to employ these methods when assessing PA in patients with CF.  421 
4.3 The relationship between PA and secondary outcomes 422 
The evidence for an association between PA and lung function was inconsistent with 5/9 423 
finding a positive association. There appears to be stronger evidence for an association 424 
between PA and exercise capacity with all 4 studies reviewed reporting a positive association, 425 
albeit in a small number of low quality studies. Evidence of an association with PA was also 426 
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inconsistent across all other outcome measures reviewed. Additionally only one study 427 
reviewed reported a measure of QoL.  428 
The majority of studies which found an association between PA and lung function used an 429 
objective assessment of PA, with only one study finding an association using self-reported PA. 430 
Likewise, all of the studies finding an association between PA and exercise capacity used 431 
objective PA assessment, whereas the association was not evident when using a self-report 432 
questionnaire. Given the limited number of studies comparing objective and self-reported PA 433 
assessment, it is not possible to assess the influence of assessment tool on the ability to 434 
detect correlations between PA and clinical outcome measures. Though the available data 435 
would suggest that objective PA assessment may be more appropriate than self-reported 436 
methods [31]. Future research should utilise objective PA assessment wherever possible, with 437 
additional self-report methods considered alongside, in order to provide evidence for future 438 
PA guidelines. 439 
An additional consideration when exploring the relationship between PA and clinical outcome 440 
measures is that of variation in the population due to the nature of the disease. Patients will 441 
inevitably experience periods of stability and instability, and disease progression and severity 442 
is highly variable within cohorts, all of which presents challenges for monitoring PA. 443 
Exacerbations of CF symptoms and hospitalisation impact levels of PA [50]. This may result 444 
in data attrition if exacerbations occur during study monitoring periods. Additionally, PA 445 
assessed pre, during or post-exacerbation may not accurately reflect habitual PA. Routine 446 
monitoring throughout the year and not just during admissions is required to overcome this 447 
issue. Monitoring devices and cut-points need to be validated for use in CF populations, both 448 
in terms of criterion validity to gold standard measures of PA assessment and in terms of the 449 
ability to discriminate between disease severities. Additional work is required to develop 450 
disease specific cut-points. Alternatively, standardised cut-points should be agreed upon and 451 
adopted universally. 452 
4.4 Variability in reported PA variables  453 
There were a wide range of measurement tools used in the studies reviewed. Five studies 454 
used an objective method [6,11,22–25] with the remaining 12 studies using self-report 455 
questionnaires, in addition to one study using both methods [31]. Comparisons between 456 
studies are difficult due to the large range of outcomes reported (Table 2). There is no 457 
consistent variable (e.g. steps, total PA time, METs) reported meaning analysis of pooled 458 
effects was not possible. There were no consistent findings for PA in comparison to guidelines 459 
or non-CF peers when assessed using different PA assessment methods, suggesting no 460 
difference between the assessment methods used. This may be due to variances in validity 461 
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and reliability of these assessment methods as well as differences in populations’ studied and 462 
study designs. There is therefore a need for an adoption of standardised, objective measures 463 
of PA, with consistent outcomes reported. Standardisation may enable a better understanding 464 
of PA in this cohort and allow for comparisons to be made to global PA recommendations and 465 
non-CF peers. 466 
4.5 Assessment tools utilised 467 
Questionnaires may be useful for large scale epidemiological research, or as secondary 468 
outcome measures of PA, however objective PA assessment should be considered as the 469 
informed choice for PA assessment in clinical practice and research [8]. The IAPQ was the 470 
only self-report tool which allowed PA levels to be compared to guidelines in the current 471 
review. The Baecke questionnaire was the most frequently used questionnaire, used in 3 472 
studies, all of which described low levels of PA in adults with CF. Understanding of PA levels 473 
in adults with CF has previously been based on such studies though it may be possible that 474 
the Baecke questionnaire underestimates PA in this population. The questionnaire is not 475 
disease specific and was developed in healthy, individuals and may not be appropriate for use 476 
in CF populations. Whilst the IPAQ is well validated across multiple populations [51], it is not 477 
valid or appropriate for use in clinical populations such as; breast cancer [52], HIV [53] or 478 
fibromyalgia [54], which highlights the importance of validating tools in the population in which 479 
they are intended to be used. The HAES questionnaire has previously been described as a 480 
valid, reliable and responsive PA assessment tool in adolescents with CF [55]. The current 481 
review only included one study using the HAES questionnaire, the findings of which suggest 482 
that the questionnaire overestimates PA in adults with CF when compared to accelerometry 483 
[31]. The studies in the current review span almost two decades, during which time the 484 
management of CF has changed considerably. Additionally, the assessment of physical 485 
activity has also changed with the increased accessibility and use of accelerometry in the 486 
previous decade. The data available in the current review does not allow for comparisons of 487 
clinical outcome measures and PA assessment throughout this period and caution should be 488 
taken when interpreting data across such a long period. 489 
4.6 Limitations 490 
The quality of data reported in the studies reviewed limits the strength of the conclusions which 491 
can be made from this review, this review therefore highlights the need for further research in 492 
this area. The majority of the studies were graded as low quality, based primarily on a lack of 493 
a control groups and/or randomisation. The majority of studies were not specifically designed 494 
to investigate PA levels, often reporting PA as a secondary outcome measure. The non-495 
standardised reporting of outcome measures prevents any meta-analysis or collation of data 496 
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to strengthen the evidence and improve understanding of PA behaviour. Additionally, 497 
assessing the risk of bias in the studies reviewed is problematic. The tools currently available 498 
to assess risk of bias are not designed to assess studies using a cross-sectional design. 499 
Consequently, the assessment of risk of bias and the ability to make recommendations based 500 
on this assessment may be limited when using the tools currently available. 501 
CONCLUSIONS 502 
The literature reviewed would suggest that PA in adults with CF is largely comparable to their 503 
non-CF peers, despite being insufficiently active to achieve global PA recommendations. The 504 
choice of PA assessment tool and reported outcomes are highly variable, many of which do 505 
not provide sufficient information about the frequency, intensity or time of PA in adults with 506 
CF. The associations between PA and clinical outcomes appear to be stronger when using 507 
objectively assessed PA when compared to self-reported PA, although there are few studies 508 
available for analysis. The previously reported associations between PA and lung function 509 
appear to be supported by the data reviewed, although a number of studies found no 510 
associations. The association between PA and exercise capacity is also supported by data 511 
reviewed, albeit from a limited number of studies. 512 
 513 
6. FUTURE RECOMMENDATIONS  514 
The current review has highlighted a requirement for high quality studies designed specifically 515 
to explore PA in adults with CF. The increased emphasis on adults with CF is also reflected 516 
by the recently updated European Cystic Fibrosis society (ECFS) best practice guidelines, 517 
who also recognise a shift in focus to adult populations given the current trend in life 518 
expectancy. Whilst this is true for wider CF care it is particularly relevant with regards to PA 519 
assessment, given the lack of available evidence. Standardisation of PA monitoring and 520 
reporting is essential for  future research, it has previously been recommended that time spent 521 
engaging in PA of different intensities, time spent sedentary, step count and energy 522 
expenditure should be the minimum standard for reporting PA [8]. A wrist-worn accelerometer 523 
(compliance has previously been shown to be higher when using wrist worn devices [49]), 524 
worn for seven consecutive days during waking hours, using at least 10 hours per day as a 525 
minimum wear time criteria should be used to assess habitual PA [56]. Where possible raw 526 
data analysis should be used to analyse data with outcomes reported as outlined above. 527 
Standardisation will allow for comparisons between cohorts as well as data pooling to improve 528 
statistical precision. Levels of PA and its impact on health and wellbeing in CF are still not 529 
clear in the literature. Which may be attributed to the lack of high-quality research, using 530 
appropriate PA assessment methods to examine PA behaviours and the relationship with 531 
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clinical outcomes. Further work is therefore needed to fully elucidate the impact of PA in CF, 532 
with an ultimate aim of providing an evidence base to inform guidelines and clinical practice. 533 
The scope of the current review only extends to adults (≥18 years), additional reviews are 534 
required to understand any differences between paediatric and adult/mixed populations.    535 
The quality of PA assessment would benefit from an approach similar to the European CF 536 
Exercise group’s recommended guidelines for exercise testing [57]. This involved experts from 537 
a range of backgrounds from different organisations and geographical areas were involved in 538 
a process to inform the development of the guidelines [57]. The guidance recommends the 539 
standardised use of routine exercising testing in CF care, and whilst this provides an important 540 
assessment of exercise capacity, this is only one component of PA. Further assessment 541 
methods are required to assess habitual PA; a combination of exercise testing, objective and 542 
self-reported PA assessment methods should be considered in clinical practice to screen 543 
participants and inform and evaluate PA interventions.  544 
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